Social networks
743 780 10,303Activities
Technologies
Entity types
Location
203 Crescent St 17 102b, Waltham, MA 02453, USA
Waltham
United States of America
Employees
Scale: 51-200
Estimated: 158
Engaged corporates
2Added in Motherbase
5 years, 6 months agoFraming the future of autoimmune diseases
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 1 May 2018 | | |
Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Not capitalistic Not partnership Event 25 Jul 2017 31 Jul 2022 | | |